Leo Wealth LLC Purchases New Shares in GSK plc (NYSE:GSK)

Leo Wealth LLC purchased a new stake in GSK plc (NYSE:GSK) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 23,015 shares of the pharmaceutical company’s stock, valued at approximately $885,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Versant Capital Management Inc lifted its position in GSK by 2,816.7% during the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 676 shares during the period. BKM Wealth Management LLC purchased a new position in GSK during the fourth quarter valued at $32,000. Richardson Financial Services Inc. purchased a new position in GSK during the fourth quarter valued at $40,000. Jones Financial Companies Lllp lifted its position in GSK by 62.2% during the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock valued at $48,000 after buying an additional 509 shares during the period. Finally, Princeton Global Asset Management LLC lifted its position in GSK by 54.3% during the fourth quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock valued at $56,000 after buying an additional 533 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analysts Set New Price Targets

GSK has been the subject of several recent analyst reports. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. The Goldman Sachs Group initiated coverage on GSK in a research report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price target for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $47.00.

GSK Price Performance

Shares of NYSE:GSK opened at $40.67 on Tuesday. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The business has a 50-day simple moving average of $42.55 and a two-hundred day simple moving average of $41.00. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87. The firm has a market cap of $84.29 billion, a price-to-earnings ratio of 14.74, a price-to-earnings-growth ratio of 1.23 and a beta of 0.66.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.15. The business had revenue of $9.34 billion during the quarter, compared to the consensus estimate of $8.98 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%. On average, analysts expect that GSK plc will post 4.11 earnings per share for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a dividend of $0.3762 per share. This is an increase from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.70%. The ex-dividend date is Thursday, May 16th. GSK’s payout ratio is currently 53.26%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.